Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25517160 | 0.93 | BTK (0.51) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL30772750 | 0.90 | JAK1 (0.49) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL17942105 | 0.78 | EPHX2 (0.45) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL17942077 | 0.78 | EPHX2 (0.45) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL17942057 | 0.78 | — | — | |
| SCHEMBL21211467 | 0.73 | GAA (0.44) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL18263497 | 0.73 | PARP1 (0.54) | JAK1JAK2TYK2JAK3KMT2A | |
| SCHEMBL28815568 | 0.72 | THRB (0.56) | GAAJAK1JAK2TYK2JAK3 | |
| SCHEMBL22961412 | 0.70 | BTK (0.54) | GAAEPHX2BTKJAK1JAK2 | |
| SCHEMBL20099498 | 0.70 | BTK (0.53) | GAAEPHX2BTKKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | NAMPT, NQO2, NNMT | GAA 3281/4885EPHX2 3492/4885BTK 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.